US Patent 8,486,925: Scope, Claim Construction, Expiration, and Testosterone Gel Patent Landscape

US Patent 8,486,925 protects a narrowly defined 1.62% testosterone hydroalcoholic gel associated with AndroGel 1.62%. Its independent claim requires a closed composition containing testosterone, isopropyl myristate, ethanol, polyacrylic acid, sodium hydroxide, and water in specified concentrations. The dependent claims add ethanol strength, carbomer identity, neutralization conditions, and a 2.5-gram dose delivering 40.5 milligrams of testosterone.

The patent is materially narrower than a general patent covering testosterone gels. The principal infringement risk concerns products that reproduce the claimed excipient system and concentrations, not every testosterone topical product.

What does US Patent 8,486,925 cover?

The patent covers a hydroalcoholic testosterone gel with the following composition:

Component	Claim 1 concentration
Testosterone	1.62% w/w
Isopropyl myristate	1.0% w/w
Ethanol	73.5% w/w
Polyacrylic acid	1.0% w/w
0.1 N sodium hydroxide	7.0% w/w
Water	Balance

Claim 1 uses the transitional phrase “consisting of.” That language generally closes the composition to additional ingredients that materially alter the claimed formulation. A product containing an extra active ingredient or a formulation component outside the claimed system may avoid literal infringement, although the legal result depends on the function and quantity of the added ingredient.

The claim does not merely require testosterone in a gel. It requires the specific combination of:

A 1.62% w/w testosterone concentration;
1.0% w/w isopropyl myristate;
73.5% w/w ethanol;
1.0% w/w polyacrylic acid;
7.0% w/w 0.1 N sodium hydroxide; and
Water.

A formulation that omits isopropyl myristate, uses a different penetration enhancer, substitutes a different neutralizing agent, or materially changes the concentration profile may have a substantial non-infringement position.

How should the claims of US 8,486,925 be construed?

Claim 1: Closed hydroalcoholic composition

Claim 1 is the key composition claim. It requires all listed components and concentrations. Because it is written as a “consisting of” claim, the claim is narrower than a “comprising” claim.

The claim’s principal limitations are:

Testosterone must be present at 1.62% by weight.
Isopropyl myristate must be present at 1.0% by weight.
Ethanol must be present at 73.5% by weight.
Polyacrylic acid must be present at 1.0% by weight.
The sodium hydroxide component must be 7.0% by weight of 0.1 N sodium hydroxide.
Water completes the composition.

Concentration rounding is commercially important. A generic manufacturer would examine whether the proposed product falls within ordinary analytical tolerances, manufacturing specifications, and the doctrine of equivalents. A small numerical variation does not automatically eliminate infringement.

Claim 2: Approximately 95% v/v ethanol

Claim 2 limits the ethanol to about 95% by volume. This limitation describes the ethanol raw material rather than necessarily requiring the final gel to contain 95% ethanol by volume. The distinction between raw-material concentration and final-product concentration is important in manufacturing and claim analysis.

Claims 3 and 5: Neutralized polyacrylic acid

Claim 3 requires the polyacrylic acid to have been neutralized by combining:

1.0% w/w polyacrylic acid; and
7.0% w/w 0.1 N sodium hydroxide.

Claim 5 adds that the polyacrylic acid is a carbomer.

These claims provide process-related limitations within otherwise composition-focused claims. They may be relevant where a manufacturer uses the same neutralization sequence, even if the final product analysis alone does not reveal the manufacturing method.

Claims 4 and 5: Carbomer

Claim 4 specifies that the polyacrylic acid is a carbomer. Claim 5 combines the carbomer limitation with the neutralization limitation of claim 3.

A product using a different thickener, such as hydroxyethylcellulose or a non-polyacrylic polymer, would not literally satisfy the carbomer limitations. It could still raise broader formulation-patent issues under other patents, but it would have a stronger position against claims 4 and 5 specifically.

Claims 6 and 7: Dose and delivered testosterone

Claim 6 requires a therapeutically effective dose of 2.5 grams for treating hypogonadism in a human male.

Claim 7 requires that the 2.5-gram dose administer 40.5 milligrams of testosterone. That calculation follows directly from the 1.62% concentration:

2.5 grams × 1.62% = 0.0405 grams = 40.5 milligrams.

Claims 6 and 7 do not broadly cover any therapeutic use of testosterone. They are tied to the claimed gel and the specified dose. A product with the same composition but a different labeled dose may avoid these dependent claims while remaining exposed under claim 1.

What formulations are protected by US Patent 8,486,925?

The strongest literal infringement case would involve a product with all of the following characteristics:

Formulation element	Matching product characteristic
Active ingredient	Testosterone
Strength	1.62% w/w
Vehicle	Hydroalcoholic gel
Alcohol	73.5% w/w ethanol
Penetration enhancer	1.0% w/w isopropyl myristate
Polymer	1.0% w/w polyacrylic acid or carbomer
Neutralizer	7.0% w/w 0.1 N sodium hydroxide
Dose	2.5 grams
Testosterone delivered	40.5 milligrams

The patent does not appear, based on the supplied claims, to cover:

Testosterone gels at concentrations other than 1.62%;
Testosterone solutions without the claimed polymer system;
Patches, creams, injections, implants, pellets, or oral testosterone products;
Gels using a different penetration enhancer;
Gels using a different polymer;
Gels using a different neutralizer;
Products that do not contain the claimed ethanol concentration;
A generic 1% testosterone gel formulation.

This claim structure creates a meaningful design-around path. The commercial difficulty is that a substitute formulation must maintain adequate testosterone solubility, skin permeation, drying characteristics, viscosity, stability, tolerability, and dose delivery.

How strong is the patent estate for the claimed testosterone gel?

US 8,486,925 is strongest as a formulation patent and weaker as a standalone platform patent.

Strengths

Claim 1 identifies a highly specific commercial formulation.
The 1.62% strength and 2.5-gram dose align with the marketed AndroGel 1.62% product profile.
Dependent claims cover carbomer and neutralization features that may be identifiable from formulation records.
The claim provides a clear product-by-process and composition framework for ANDA litigation.

Vulnerabilities

The exact numerical limitations narrow the literal infringement analysis.
“Consisting of” limits the ability to capture materially different formulations.
The claim does not cover testosterone generally.
A competitor may avoid the claim by modifying the polymer, penetration enhancer, neutralizer, ethanol concentration, or testosterone strength.
Validity may be tested against earlier testosterone gel formulations, carbomer gels, alcohol-based transdermal systems, and formulation optimization references.

The patent’s commercial value therefore depends heavily on whether the accused product is intended to be substitutable with the reference product and whether the manufacturer chooses a close formulation for regulatory or manufacturing reasons.

What is the Orange Book status of US 8,486,925?

The patent was listed in connection with AndroGel 1.62%, an FDA-approved testosterone topical gel marketed by AbbVie-related entities. The Orange Book is the controlling public source for patents submitted for FDA-approved small-molecule drug products and for the listed patent-use codes. FDA’s Orange Book framework distinguishes patents covering drug substances, drug products, and approved methods of use.[1]

US 8,486,925 is a drug-product or formulation patent rather than a patent claiming testosterone as a chemical entity. Its relevance is therefore concentrated in ANDA certification and product-specific infringement litigation.

For an ANDA applicant, the principal pathways are:

Paragraph III certification, agreeing not to market until patent expiration;
Paragraph IV certification, asserting that the patent is invalid, unenforceable, or not infringed; or
A section viii statement, where the applicant omits a patented method of use that is not necessary for the proposed label.

A formulation patent generally cannot be removed through a section viii carve-out if the patent is listed against the drug product rather than only against a particular method of use.

When does US 8,486,925 lose exclusivity?

Public drug-patent records identify August 31, 2025, as the listed expiration date associated with US 8,486,925. The operative commercial date should be confirmed against the current FDA Orange Book patent table and any applicable patent-term adjustment or disclaimer information.[1][2]

The relevant timeline is:

Event	Date or period
Patent application and prosecution	Before issuance
Patent issuance	July 23, 2013
Listed patent expiration	August 31, 2025
FDA regulatory exclusivity	Separate from patent term
Generic entry	Subject to ANDA approval, certification status, litigation, and any settlement restrictions

Patent expiration does not guarantee immediate generic competition. FDA approval timing, manufacturing readiness, court orders, authorized-generic arrangements, and settlement terms can affect the actual launch date.

What Paragraph IV challenges and litigation risks affect the patent?

A Paragraph IV applicant would attack the patent through two principal theories:

Non-infringement

The applicant could argue that its product does not contain one or more required components or concentrations. The most practical arguments would involve:

A different amount of ethanol;
A different carbomer or polymer concentration;
A substitute penetration enhancer;
A different neutralization system;
A testosterone concentration outside 1.62% w/w;
A formulation with additional ingredients inconsistent with the “consisting of” language.

The applicant would also assess whether the ANDA product’s inactive-ingredient specifications permit batches that fall within the claim.

Invalidity

Potential invalidity theories would focus on:

Anticipation by an earlier testosterone gel formulation;
Obviousness based on known testosterone gels and routine formulation optimization;
Written-description or enablement issues concerning the exact composition;
Indefiniteness involving “about” and concentration measurements;
Patent-term or priority issues, where relevant.

The 1.62% strength, 2.5-gram dose, and 40.5-milligram delivery limitation could support an unexpected-results argument if the patent record contains comparative data. Without such evidence, an opponent would characterize the claimed concentrations as routine optimization of a known transdermal gel.

A timely Paragraph IV suit by the patent owner can trigger the Hatch-Waxman 30-month stay under 21 U.S.C. § 355(j)(5)(B)(iii), subject to statutory exceptions and court action.[3]

Which companies are associated with the competing testosterone gel market?

The competitive field includes branded and generic testosterone gels, but competitors do not necessarily practice the claims of US 8,486,925.

Product category	Examples	Relationship to the patent
Branded 1.62% testosterone gel	AndroGel 1.62%, AbbVie	Product most closely associated with the claimed formulation
Generic 1.62% testosterone gel	FDA-approved ANDA products	Potentially subject to Paragraph IV litigation or licensed entry
1% testosterone gel	Generic and branded testosterone gels	Different strength; not automatically within claim 1
Testosterone solution	Axiron-type products and successors	Different dosage form and formulation architecture
Testosterone patch	Transdermal patch products	Outside the hydroalcoholic gel claims
Injectable testosterone	Testosterone cypionate, enanthate, undecanoate	Outside the claimed dosage form

Because testosterone is a small molecule, biosimilar approval is not relevant. Competing products proceed through the generic-drug framework, primarily ANDAs, rather than the biologics pathway under the Public Health Service Act.

What manufacturing and intellectual-property barriers remain?

The principal manufacturing barrier is reproducing a stable, cosmetically acceptable gel with reliable transdermal delivery. The formulation must control:

Testosterone dissolution;
Carbomer hydration and viscosity;
Neutralization endpoint;
Ethanol evaporation;
Isopropyl myristate dispersion;
Microbial quality;
Container compatibility;
Dose uniformity;
Skin permeation and transfer risk.

Even when a competitor designs around US 8,486,925, other intellectual-property rights may remain relevant. These can include:

Additional formulation patents;
Container and metering-pump patents;
Manufacturing-process patents;
Method-of-use patents;
Transdermal delivery patents;
Trade secrets concerning mixing order, neutralization, and filling conditions;
Regulatory exclusivity or settlement restrictions.

The supplied claims alone do not establish freedom to operate for a competing testosterone gel.

How does US 8,486,925 compare with broader testosterone patents?

US 8,486,925 is narrower than patents claiming:

Testosterone as an active pharmaceutical ingredient;
A broad class of androgen formulations;
Any transdermal testosterone treatment;
General treatment of male hypogonadism;
Broad alcohol-polymer gel systems.

It is stronger than a broad-use patent against a close-copy generic because the claim maps directly onto a commercial product formulation. Its value declines sharply when a competitor uses a materially different excipient system.

The principal commercial distinction is between product substitution and therapeutic substitution. A generic seeking pharmaceutical equivalence to AndroGel 1.62% may face greater formulation and litigation exposure. A competitor selling a different testosterone dosage form may compete clinically without approaching the asserted claim limitations.

Key Takeaways

US 8,486,925 is a narrow formulation patent for a 1.62% testosterone hydroalcoholic gel.
Claim 1 requires a closed composition with exact concentrations of testosterone, isopropyl myristate, ethanol, polyacrylic acid, sodium hydroxide, and water.
Claims 4 and 5 specifically cover carbomer-based versions, including a defined neutralization system.
Claims 6 and 7 cover a 2.5-gram dose delivering 40.5 milligrams of testosterone.
The patent is most relevant to AndroGel 1.62% and closely corresponding ANDA products.
A substitute polymer, penetration enhancer, neutralizer, ethanol level, or testosterone strength may create a non-infringement position.
Biosimilar risk does not apply because testosterone is a small-molecule drug.
The listed patent expiration date is August 31, 2025, subject to the operative FDA and USPTO records.
Patent expiration does not by itself determine the actual generic launch date.
Other formulation, manufacturing, device, method-of-use, and trade-secret rights may remain after this patent expires.

FAQs

Does US 8,486,925 cover all 1.62% testosterone gels?

No. The product must also satisfy the claimed excipient and concentration limitations, including isopropyl myristate, ethanol, polyacrylic acid, sodium hydroxide, and water.

Can a generic avoid US 8,486,925 by using a different carbomer?

Possibly. Claims 4 and 5 require a carbomer, but claim 1 broadly recites polyacrylic acid. A different carbomer may still fall within the claim depending on how it is characterized and whether all other limitations are met.

Is 40.5 milligrams the amount of testosterone in the full daily dose?

Under claim 7, yes. The claim ties a 2.5-gram application to delivery of 40.5 milligrams of testosterone based on the 1.62% concentration.

Does patent expiration eliminate FDA exclusivity?

No. Patent expiration and FDA regulatory exclusivity are separate. FDA approval requirements, ANDA timing, litigation outcomes, and settlement provisions can affect market entry.

Can a testosterone cream avoid this patent?

A cream may avoid the hydroalcoholic gel claim if it does not meet the claimed composition and dosage-form limitations. It may still implicate other patents or regulatory requirements.

References

U.S. Food and Drug Administration. (2025). Approved drug products with therapeutic equivalence evaluations: Orange Book. https://www.fda.gov/drugsatfda
United States Patent and Trademark Office. (2013). U.S. Patent No. 8,486,925, Testosterone gel formulation. https://patents.google.com/patent/US8486925
U.S. Code. (2024). 21 U.S.C. § 355(j): Abbreviated applications for new drugs. https://uscode.house.gov/

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Patented / Exclusive Use	Submissiondate
Besins Hlthcare	ANDROGEL	testosterone	GEL, METERED;TRANSDERMAL	022309-001	Apr 29, 2011	AB	RX	Yes	Yes	8,486,925	⤷ Start Trial	Y				⤷ Start Trial
Besins Hlthcare	ANDROGEL	testosterone	GEL;TRANSDERMAL	022309-002	Sep 7, 2012	AB2	RX	Yes	No	8,486,925	⤷ Start Trial	Y				⤷ Start Trial
Besins Hlthcare	ANDROGEL	testosterone	GEL;TRANSDERMAL	022309-003	Sep 7, 2012	AB2	RX	Yes	No	8,486,925	⤷ Start Trial	Y				⤷ Start Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Patented / Exclusive Use	>Submissiondate

Country	Patent Number	Estimated Expiration	Supplementary Protection Certificate	SPC Country	SPC Expiration
Australia	2006299833	⤷ Start Trial
Brazil	PI0617294	⤷ Start Trial
Canada	2624788	⤷ Start Trial
China	101287470	⤷ Start Trial
>Country	>Patent Number	>Estimated Expiration	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration

Details for Patent: 8,486,925

Which drugs does patent 8,486,925 protect, and when does it expire?

Summary for Patent: 8,486,925